Safe harbour statement

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This presentation has been prepared for information purposes only and the information contained herein (unless otherwise indicated) has been provided by Siemens Healthineers AG. It does not constitute or form part of, and should not be construed as, an offer of, a solicitation of an offer to buy, or an invitation to subscribe for, underwrite or otherwise acquire, any securities of Siemens Healthineers AG or any existing or future member of the Siemens Healthineers Group (the “Group”) or Siemens AG, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Siemens Healthineers AG, any member of the Group or Siemens AG or with any other contract or commitment whatsoever. This presentation does not constitute a prospectus in whole or in part, and any decision to invest in securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of Siemens Healthineers AG, unless otherwise indicated, as of the date indicated and are subject to change without notice.

Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these assumptions, views or opinions in light of developments which differ from those anticipated.

All information not separately sourced is from internal company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is not intended to predict actual results, and no assurances are given with respect thereto.

The information contained in this document has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of Siemens Healthineers AG or any of its affiliates, advisers, affiliated persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation. This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction which may not lawfully be disclaimed (including in relation to fraudulent misrepresentation).

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations, plans and certain assumptions of Siemens Healthineers’ management, of which many are beyond Siemens Healthineers’ control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those possibly described in the respective disclosures. Should one or more of these or other risks, uncertainties or factors (e.g. events of force majeure, including but not limited to unrest or acts of war) materialize, plans change or should underlying expectations not occur or assumptions prove incorrect, Siemens Healthineers’ management actions, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the forward-looking statement.

This document includes supplemental financial measures that are or may be alternative performance measures not precisely defined in the applicable financial reporting framework (non-GAAP measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, and therefore they may not be comparable to those included in this document.

Please find further explanations regarding our (supplemental) financial measures in chapter “A.2 Financial performance system” and in the Notes to consolidated financial statements, Note 29 “Segment information” of the Annual Report 2021 of Siemens Healthineers. Additional information is also included in the Quarterly Statement. These documents can be found under the following internet link https://www.siemens-healthineers.com/investor-relations/presentations-financial-publications.

Due to rounding, individual numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements.

This document is an English language translation of the German document. In case of discrepancies, the German language document is the sole authoritative and universally valid version.

The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice. In the event that the male form is used in this document, the information nevertheless refers to all persons (male, female, non-binary).
Growth and resilience in a challenging environment

• **Remarkable momentum** in order and revenue growth *continued*: equipment book-to-bill at 1.22, comparable revenues up 16% despite unprecedented challenges

• **Diagnostics revenue with outstanding growth** of 37% incl. ~€680m of rapid antigen sales

• **Strong revenue growth in Imaging and Advanced Therapies** with 6% and 8% respectively

• **Varian** with €706m revenue contribution; strong equipment book-to-bill of 1.31

• **Adj. EBIT margin** of 17.9% holding up well despite FX headwinds and further increased procurement and logistics costs, on back of significant rapid antigen contribution

• **Adj. basic EPS** of €0.67 up +53% y-o-y

• **Outlook 2022 raised** to 5.5-7.5% revenue growth and €2.25-2.35 adj. basic EPS, new rapid antigen revenue assumption of ~€1,300m

*Note: All growth rates are year-over-year on a comparable basis, see glossary*
Our unique capabilities

Patient Twinning
Personalization of diagnosis, therapy selection and monitoring, after care and managing health

Precision Therapy
Intelligent and image guided treatment for the most threatening diseases

Digital, Data and AI
Leveraging digital, data and AI and advance providers’ operations with tech-enabled and enterprise services
Our strategic growth vectors

Patient Twinning

Imaging

Diagnostics

Precision Therapy

Varian

Advanced Therapies

Fighting most threatening diseases

Enabling efficient operations

Expanding access to care

Digital, Data and AI
Our unmatched relevance

Unique customer access
- Unmatched C-level relationships
- addressing all major departments
- addressing all major disease states

Unique suite of offerings
- Leading products
- Best-in-class service
- Renown consulting
- Value Partnerships

Unique track record
- Continuous share gains
- Leading Net Promoter Scores
- >€3bn backlog of long-term partnership agreements

Note: orange marked hospital departments are served with Siemens Healthineers products and services
Growth and resilience in a challenging environment

Unmatched global presence
balancing the impacts of COVID-19 lockdowns

Innovative product portfolio
serving unchanged underlying growth drivers

Pricing excellence
based on innovation leadership

Robust set-up and highly professional team managing global supply chain challenges

Agile organization capturing COVID-19 pandemic opportunities
(e.g. rapid antigen business)
Growth and resilience in revenue and earnings per share in a challenging environment

- 15.8% revenue growth in Q2 with growth across the board
- Ex-antigen growth at 4.4% on tough comps (PYQ: ~8% ex-antigen)
- Americas with 33% growth driven by antigen contribution and continuing underlying momentum (~9% ex-antigen)
- EMEA with 12% growth driven by antigen contribution and continuing underlying momentum (~6% ex-antigen)
- Asia, Australia down y-o-y with -1% driven by China on tough comps and impact from lockdowns (China: Q2 22: -10% vs. Q2 21: +17%)

- Adj. basic EPS up +53% y-o-y on higher revenue
- Adj. EBIT margin at 17.9%, holding up well despite FX headwinds and further increased procurement and logistics costs, on back of significant rapid antigen contribution
- Financial income net in Q2 at -€7m
- Tax rate at 23% due to positive tax procedure (PYQ: 27%)
Strong growth in all segments; margins impacted by FX and further increased procurement and logistics costs

**Comparative Growth**

<table>
<thead>
<tr>
<th></th>
<th>Imaging (€m)</th>
<th>Diagnostics (€m)</th>
<th>Advanced Therapies (€m)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adjusted revenue</strong></td>
<td>2,368</td>
<td>1,237</td>
<td>408</td>
</tr>
<tr>
<td>Q2 FY2021</td>
<td>2,621</td>
<td>1,768</td>
<td>456</td>
</tr>
<tr>
<td>Q2 FY2022</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Margin Y-o-Y**

- **Imaging**
  - **Q2 FY2021**: 499 (21.1%)
  - **Q2 FY2022**: 530 (20.2%)
  - **Change**: -90 bps

- **Diagnostics**
  - **Q2 FY2021**: 131 (10.6%)
  - **Q2 FY2022**: 342 (19.3%)
  - **Change**: +870 bps

- **Advanced Therapies**
  - **Q2 FY2021**: 58 (14.2%)
  - **Q2 FY2022**: 55 (12.0%)
  - **Change**: -220 bps

**Adj. EBIT (margin)**

- **Imaging**
  - **Q2 FY2021**: 2,368
  - **Q2 FY2022**: 2,621

- **Diagnostics**
  - **Q2 FY2021**: 1,237
  - **Q2 FY2022**: 1,768

- **Advanced Therapies**
  - **Q2 FY2021**: 408
  - **Q2 FY2022**: 456

**Notes**

1. MR: Magnetic Resonance, CT: Computed Tomography
2. Ex rapid antigen

**Key Points**

- **Imaging**
  - Continued strong growth in Q2 with very strong growth in MR and CT
  - Margin down year-over-year on FX headwinds and further increased procurement and logistics costs (Σ ~250 bps)

- **Diagnostics**
  - Revenue significantly up, driven by higher rapid antigen test revenues y-o-y, core revenues impacted by China lockdowns
  - Margin up y-o-y driven by significant rapid antigen contribution, overcompensating headwinds from FX and further increased procurement and logistics costs (Σ ~400 bps)
  - Ongoing invest in Corindus

- **Advanced Therapies**
  - Strong growth in Q2
  - Margin down y-o-y on headwinds from FX and further increased procurement and logistics costs (Σ ~200 bps)
Varian – solid quarter with further expanding order backlog

- Strong order backlog continues to expand, showing track record for positive equipment book-to-bill
- Signed multi-year multidisciplinary oncology service agreement with the Cancer Treatment Centers of America
- Soft y-o-y revenue growth in Q2 impacted by push-outs to Q3 e.g. due to lockdowns in China
- Profitability in-line with seasonality, impacted by revenue push-outs and further increased procurement and logistics costs

<table>
<thead>
<tr>
<th>Equipment book-to-bill</th>
<th>1.31x</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted revenue(^1)</td>
<td>€706m</td>
</tr>
<tr>
<td>Adj. EBIT margin</td>
<td>13.3%</td>
</tr>
</tbody>
</table>

\(^1\) Adj. for effects in line with revaluation of contract liabilities from IFRS 3 PPA, see glossary
Imaging – margin expected to significantly pick up in H2

Proven track-record of industry-leading (gross) margins

<table>
<thead>
<tr>
<th>Gross Margins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Now</td>
</tr>
<tr>
<td>New Ambition</td>
</tr>
</tbody>
</table>

- **Pricing**
  - Pricing discipline across the board and pricing strength from innovation leadership positions

- **Productivity**
  - 4 to 5% p.a. of total cost productivity from design-to-cost, purchasing and lean processes through digitalisation

- **Scale**
  - Scaling purchasing power and cost deflation on growing revenues

- **Price erosion**
  - Pricing headwind historically between -1.5% to -2.5% p.a., decreasing in recent years - no material change expected

Imaging margin drivers H2 vs. H1

- **Scale** drives cost deflation in H2 (H2 revenues ~€0.5bn up vs. H1)
- **FX headwinds** in H1 (> -100 bps) falling to ~0 in H2
- **Pricing measures** impact H2
- Increased **procurement and logistics costs**

The Siemens Healthineers set-up for industry-leading (gross) margins

- **Inflation**
  - Cost inflation offset by decreasing headwinds in price erosion

- **FX**
  - More balanced exposure to €/$-rate with VaR analytics value-add in $; hedging on a rolling basis to reduce volatility
Diagnostics – rapid antigen business more than compensates headwinds from FX and procurement and logistics costs

- New rapid antigen assumption for FY22 of ~€1,300m [before: €700m] due to demand in the U.S., sharp “cliff-like” demand drop assumed in H2; ~€1,000m revenue in H1
- FY22 rapid antigen revenue assumed to be 50/50 EMEA and U.S., H2 revenue mostly in the U.S.
- Diagnostics ex rapid antigen posts y-o-y flattish revenue in Q2, muted due to China lockdowns; solid growth in the U.S.

- Q2 Diagnostics profitability with significant antigen contribution
- Accretion expected to decline significantly in H2 due to lower volumes
- Diagnostics ex rapid antigen soft due to valuation effects in Q2, underlying profitability in the mid-single digits

Note: indicative graph only, not to scale, excl. valuation effects
Outlook FY2022 raised

Comparable revenue growth

- Imaging growth at 6 to 8% (before: 5 to 8%)
- Diagnostics growth at mid-single digits (before low-single digit negative growth), rapid antigen revenue assumed at ~€1,300m in FY22 (before: ~€700m)
- Varian revenue\(^1\) at €2.9 to €3.1bn in FY22, growth at low teens, contributing to comparable growth in H2 only
- Advanced Therapies growth at 5 to 8%

Adj. basic earnings per share

- Imaging margin at 21 to 22% (before: 22 to 23%)
- Diagnostics margin at low to mid-teens (before: low teens)
- Varian margin at 15 to 17%
- Advanced Therapies margin at 14 to 17%
- Financial income, net at €-50m to €-70m
- Tax rate at 27% to 29%

Note: The outlook is based on current foreign exchange rate assumptions, on the current portfolio and on further assumptions, see Quarterly Statement Q2 FY2022

\(^1\) Adj. for effects in line with revaluation of contract liabilities from IFRS 3 PPA, see glossary
Q2 FY22 cash conversion held back by inventory buildup and incentive payouts

Q2 FY22 Siemens Healthineers EBIT to Free Cash Flow (€m)

CCR = (Free Cash Flow pre tax - Repayment of 3rd party lease liabilities) / (Healthineers EBIT excl. PPA)

<table>
<thead>
<tr>
<th>Category</th>
<th>Value (€m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthineers EBIT</td>
<td>761</td>
</tr>
<tr>
<td>PPA Amortization</td>
<td>186</td>
</tr>
<tr>
<td>EBIT excl. PPA Amortization &amp; Intang. excl. PPA</td>
<td>947</td>
</tr>
<tr>
<td>EBITDA</td>
<td>1116</td>
</tr>
<tr>
<td>Change in OWC</td>
<td>-137</td>
</tr>
<tr>
<td>Change in other assets &amp; liabilities</td>
<td>-338</td>
</tr>
<tr>
<td>Add. to operating leases</td>
<td>-75</td>
</tr>
<tr>
<td>Other</td>
<td>40</td>
</tr>
<tr>
<td>Operating Cash Flow pre tax</td>
<td>605</td>
</tr>
<tr>
<td>Add. to intangible assets, PPE</td>
<td>-219</td>
</tr>
<tr>
<td>Repayment of 3rd party lease liabilities</td>
<td>-39</td>
</tr>
<tr>
<td>Income taxes</td>
<td>-223</td>
</tr>
<tr>
<td>Repayment of 3rd party lease liabilities</td>
<td>-164</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>116</td>
</tr>
</tbody>
</table>

CCR values by segment:
- Imaging: 0.6
- Diagnostics: 0.3
- Varian Adv. Therapies: 1.8

1 CCR = (Free Cash Flow pre tax - Repayment of 3rd party lease liabilities) / (Healthineers EBIT excl. PPA)
FY22 balance sheet and net debt bridge

Net debt overview

<table>
<thead>
<tr>
<th>in €bn</th>
<th>Sep 30, 2021</th>
<th>Mar 31, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>1.3</td>
<td>1.1</td>
</tr>
<tr>
<td>Current receivables and receivables from the Siemens Group from financing activities</td>
<td>0.6</td>
<td>0.9</td>
</tr>
<tr>
<td>Short-term and long-term financial debt</td>
<td>(0.7)</td>
<td>(0.7)</td>
</tr>
<tr>
<td>Current liabilities and liabilities to the Siemens Group from financing activities²</td>
<td>(13.1)</td>
<td>(13.7)</td>
</tr>
<tr>
<td>Net debt</td>
<td>(11.9)</td>
<td>(12.4)</td>
</tr>
<tr>
<td>Provisions for pensions and similar obligations</td>
<td>(0.9)</td>
<td>(0.8)</td>
</tr>
<tr>
<td>Net debt (incl. pensions)</td>
<td>(12.8)</td>
<td>(13.2)</td>
</tr>
</tbody>
</table>

Capital structure development in FY22 (in €bn)

<table>
<thead>
<tr>
<th></th>
<th>1-Oct-21</th>
<th>CF from operating act.</th>
<th>CF from investing act.</th>
<th>CF from financing act. and Others</th>
<th>31-Mar-22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pensions</td>
<td>12.8</td>
<td>0.9</td>
<td>-1.1</td>
<td>0.4</td>
<td>13.2</td>
</tr>
<tr>
<td>Net Debt</td>
<td>11.9</td>
<td>1.3</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Leverage is net debt incl. pension over EBITDA rolling four quarters  
2 Includes market values from derivatives
SHS loan maturity profile

**SHS loans with Siemens Group as of Mar 31st, 2022** (in €m)

- **Other**
- **EUR**
- **USD**

### Maturity profile based on Fiscal Year start October 1

- Translation to EUR according to spot rate as of Mar 31st, 2021 (applicable for unhedged loans)

### USD loans addressed by SHS debt & capital restructuring resulting in synthetic EUR debt

- EUR volume and interest rates are calculated with underlying hedge rates

### Average interest rate p.a.

- Total loan volume ~€13bn equivalent
- Average interest rate ~0.5% p.a.

### Top 10 loans ranked in € volume

<table>
<thead>
<tr>
<th>Currency</th>
<th>Notional</th>
<th>Volume in m</th>
<th>Volume in €m</th>
<th>Interest rate</th>
<th>Maturity</th>
</tr>
</thead>
<tbody>
<tr>
<td>USD</td>
<td>$1,689</td>
<td>€1,514²</td>
<td>0.26%²</td>
<td>FY 2027</td>
<td></td>
</tr>
<tr>
<td>USD</td>
<td>$1,742</td>
<td>€1,456²</td>
<td>0.08%²</td>
<td>FY 2026</td>
<td></td>
</tr>
<tr>
<td>USD</td>
<td>$1,740</td>
<td>€1,454²</td>
<td>0.59%²</td>
<td>FY 2031</td>
<td></td>
</tr>
<tr>
<td>USD</td>
<td>$1,497</td>
<td>€1,251²</td>
<td>-0.14%²</td>
<td>FY 2024</td>
<td></td>
</tr>
<tr>
<td>USD</td>
<td>$1,486</td>
<td>€1,242²</td>
<td>1.40%²</td>
<td>FY 2041</td>
<td></td>
</tr>
<tr>
<td>USD</td>
<td>$1,247</td>
<td>€1,043²</td>
<td>-0.26%²</td>
<td>FY 2023</td>
<td></td>
</tr>
<tr>
<td>USD</td>
<td>$1,243</td>
<td>€1,039²</td>
<td>0.31%²</td>
<td>FY 2028</td>
<td></td>
</tr>
<tr>
<td>USD</td>
<td>$990</td>
<td>€892</td>
<td>3.44%</td>
<td>FY 2046</td>
<td></td>
</tr>
<tr>
<td>EUR</td>
<td>€850</td>
<td>€850</td>
<td>0.30%⁴</td>
<td>FY 2022</td>
<td></td>
</tr>
<tr>
<td>USD</td>
<td>$998</td>
<td>€834²</td>
<td>-0.15%²,⁴</td>
<td>FY 2024</td>
<td></td>
</tr>
</tbody>
</table>

---

1 Maturity profile based on Fiscal Year start October 1 - translation to EUR according to spot rate as of Mar 31st, 2021 (applicable for unhedged loans)

2 USD loans addressed by SHS debt & capital restructuring resulting in synthetic EUR debt; EUR volume and interest rates are calculated with underlying hedge rates

3 Average interest rate p.a. year-to-date after implementation of debt and capital restructuring

4 Floating interest rate
Provisions for pensions decreased mainly due to increased discount rates

Q2 FY2022 Key financials – Pensions and similar obligations

<table>
<thead>
<tr>
<th>in €bn¹</th>
<th>FY2018</th>
<th>FY2019</th>
<th>FY2020</th>
<th>FY2021</th>
<th>Q1 FY2022</th>
<th>Q2 FY2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defined benefit obligation (DBO)</td>
<td>(3.4)</td>
<td>(3.8)</td>
<td>(3.8)</td>
<td>(4.1)</td>
<td>(4.1)</td>
<td>(3.8)</td>
</tr>
<tr>
<td>Fair value of plan assets</td>
<td>2.6</td>
<td>2.8</td>
<td>2.8</td>
<td>3.3</td>
<td>3.4</td>
<td>3.2</td>
</tr>
<tr>
<td>Provisions for pensions and similar obligations²</td>
<td>(0.8)</td>
<td>(1.0)</td>
<td>(1.0)</td>
<td>(0.9)</td>
<td>(0.9)</td>
<td>(0.8)</td>
</tr>
<tr>
<td>Discount rate</td>
<td>2.9%</td>
<td>1.8%</td>
<td>1.5%</td>
<td>1.7%</td>
<td>1.6%</td>
<td>2.4%</td>
</tr>
<tr>
<td>Interest Income</td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Actual return on plan assets (after expenses)</td>
<td>0.1</td>
<td>0.3</td>
<td>0.1</td>
<td>0.2</td>
<td>0.1</td>
<td>(0.1)</td>
</tr>
</tbody>
</table>

¹ All figures are reported on a continuing basis  | ² Provisions for pensions and similar obligations does not include net defined benefit assets (Q2 FY2022: €+0.1bn) presented in the line item other assets; Defined Benefit Obligation (DBO) including other post-employment benefit plans (OPEB) of ~€-0.1bn
**Glossary**

**Adjusted revenue**

is defined as consolidated revenue reported in the company’s consolidated statements of income adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations.

**Comparable revenue growth**

is defined as the development of adjusted revenue, respectively, net of currency translation effects, which are beyond our control, and portfolio effects, which involve business activities that are either new to our business or no longer a part of it.

**EBITDA**

is defined as income before income taxes, interest income and expenses, other financial income, net as well as amortization, depreciation & impairments.

**Adjusted EBIT (adj. EBIT)**

is defined as income before income taxes, interest income and expenses and other financial income, net, adjusted for expenses for portfolio-related measures, severance charges. In addition, centrally carried pension service and administration expenses are excluded from adjusted EBIT of the segments.

**Adjusted EBIT margin (adj. EBIT margin)**

is defined as the adjusted EBIT, divided by its adjusted total revenue.

**Adjusted basic earnings per share (adj. basic EPS)**

is defined as basic earnings per share, adjusted for portfolio-related measures and severance charges, net of tax.

**Free cash flow (FCF)**

comprises the cash flows from operating activities and additions to intangible assets and property, plant and equipment included in cash flows from investing activities.

Please find further explanations regarding our financial key performance indicators in chapter “A.2 Financial performance system” and in the notes to the consolidated financial statements note 29 “Segment information” in the Annual Report 2021 of Siemens Healthineers. Additional information is also included in the Quarterly Statement. These documents can be found under the following internet link https://www.siemens-healthineers.com/investor-relations/presentations-financial-publications.